Indications, Efficacy, and Safety of Intranasal Corticosteriods in Rhinosinusitis

Simple item page
dc.contributor.authorPotter, Paulen_ZA
dc.contributor.authorPawankar, Rubyen_ZA
dc.date.accessioned2015-11-18T04:02:58Z
dc.date.available2015-11-18T04:02:58Z
dc.date.issued2012en_ZA
dc.description.abstractRhinosinusitis is a significant health problem, causing significant morbidity and resulting in considerable financial cost. Some patients suffer persistent or recurrent symptoms despite receiving optimal medical and surgical treatment. Rhinosinusitis can be acute or chronic, acute often due to viral or bacterial infections and chronic which is classified into chronic with nasal polyposids or chronic rhinosinusitis without nasal polyposis. The disease affects the quality of life significantly and presents a significant burden on health costs globally. The anatomical linkage of the nose with the paranasal sinuses facilitates a common pathology in both organs. Chronic rhinosinusitis (CRS) has heterogeneous origins, including viruses, bacteria, fungal infections, anatomical abnormalities, polyposis, and aspirin sensitivity. Other conditions such as human immunodeficiency virus acquired immunodeficiency and cystic fibrosis may also be predisposing factors. Nasal polyposis is often associated with increased numbers of Th2 lymphocytes, fibroblasts, goblet cells, mast cells, and eosinophils, with upregulation of IL-13 and the release of specific IgE to staphylococcal enterotoxins. There is recent evidence that antibiotic treatment may not be as effective as higher doses of intranasal steroids in acute uncomplicated rhinosinusitis, especially in those with allergic disease. The broad inflammatory basis of the pathology of CRS also reveals a cellular infiltrate theoretically suppressed by intranasal corticosteroids. This has been confirmed in recent clinical studies of CRS with or without polyps. A treatment approach based on such studies reported in the European Position Paper on Rhinosinusitis guidelines and a guideline summary are presented. The current review represents the proceedings of a session (3 talks) by the authors at the first Middle East-Asia Allergy, Asthma, Immunology Congress in 2009.en_ZA
dc.identifier.apacitationPotter, P., & Pawankar, R. (2012). Indications, Efficacy, and Safety of Intranasal Corticosteriods in Rhinosinusitis. <i>World Allergy Organization Journal</i>, http://hdl.handle.net/11427/15106en_ZA
dc.identifier.chicagocitationPotter, Paul, and Ruby Pawankar "Indications, Efficacy, and Safety of Intranasal Corticosteriods in Rhinosinusitis." <i>World Allergy Organization Journal</i> (2012) http://hdl.handle.net/11427/15106en_ZA
dc.identifier.citationPotter, P. C., & Pawankar, R. (2012). Indications, efficacy, and safety of intranasal corticosteriods in rhinosinusitis. The World Allergy Organization journal, 5(Suppl 1), S14.en_ZA
dc.identifier.ris TY - Journal Article AU - Potter, Paul AU - Pawankar, Ruby AB - Rhinosinusitis is a significant health problem, causing significant morbidity and resulting in considerable financial cost. Some patients suffer persistent or recurrent symptoms despite receiving optimal medical and surgical treatment. Rhinosinusitis can be acute or chronic, acute often due to viral or bacterial infections and chronic which is classified into chronic with nasal polyposids or chronic rhinosinusitis without nasal polyposis. The disease affects the quality of life significantly and presents a significant burden on health costs globally. The anatomical linkage of the nose with the paranasal sinuses facilitates a common pathology in both organs. Chronic rhinosinusitis (CRS) has heterogeneous origins, including viruses, bacteria, fungal infections, anatomical abnormalities, polyposis, and aspirin sensitivity. Other conditions such as human immunodeficiency virus acquired immunodeficiency and cystic fibrosis may also be predisposing factors. Nasal polyposis is often associated with increased numbers of Th2 lymphocytes, fibroblasts, goblet cells, mast cells, and eosinophils, with upregulation of IL-13 and the release of specific IgE to staphylococcal enterotoxins. There is recent evidence that antibiotic treatment may not be as effective as higher doses of intranasal steroids in acute uncomplicated rhinosinusitis, especially in those with allergic disease. The broad inflammatory basis of the pathology of CRS also reveals a cellular infiltrate theoretically suppressed by intranasal corticosteroids. This has been confirmed in recent clinical studies of CRS with or without polyps. A treatment approach based on such studies reported in the European Position Paper on Rhinosinusitis guidelines and a guideline summary are presented. The current review represents the proceedings of a session (3 talks) by the authors at the first Middle East-Asia Allergy, Asthma, Immunology Congress in 2009. DA - 2012 DB - OpenUCT DO - 10.1186/1939-4551-5-S1-S14 DP - University of Cape Town J1 - World Allergy Organization Journal LK - https://open.uct.ac.za PB - University of Cape Town PY - 2012 T1 - Indications, Efficacy, and Safety of Intranasal Corticosteriods in Rhinosinusitis TI - Indications, Efficacy, and Safety of Intranasal Corticosteriods in Rhinosinusitis UR - http://hdl.handle.net/11427/15106 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/15106
dc.identifier.urihttp://dx.doi.org/10.1186/1939-4551-5-S1-S14
dc.identifier.vancouvercitationPotter P, Pawankar R. Indications, Efficacy, and Safety of Intranasal Corticosteriods in Rhinosinusitis. World Allergy Organization Journal. 2012; http://hdl.handle.net/11427/15106.en_ZA
dc.language.isoengen_ZA
dc.publisherBioMed Central Ltden_ZA
dc.publisher.departmentDepartment of Public Health and Family Medicineen_ZA
dc.publisher.facultyFaculty of Health Sciencesen_ZA
dc.publisher.institutionUniversity of Cape Town
dc.rightsThis is an Open Access article distributed under the terms of the Creative Commons Attribution Licenseen_ZA
dc.rights.holder2012 World Allergy Organization; licensee BioMed Central Ltd.en_ZA
dc.rights.urihttp://creativecommons.org/licenses/by/2.0en_ZA
dc.sourceWorld Allergy Organization Journalen_ZA
dc.source.urihttp://www.waojournal.org/en_ZA
dc.subject.otherrhinosinusitisen_ZA
dc.subject.othernasal polyposisen_ZA
dc.subject.othercorticosteroidsen_ZA
dc.titleIndications, Efficacy, and Safety of Intranasal Corticosteriods in Rhinosinusitisen_ZA
dc.typeJournal Articleen_ZA
uct.type.filetypeText
uct.type.filetypeImage
uct.type.publicationResearchen_ZA
uct.type.resourceArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Potter_Indications_Efficacy_Safety_2012.pdf
Size:
130.44 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Journal Articles